Want to see FR:NANO full AI Analyst Report?
NANO Stock Chart & Stats
€28.70
<€0.01(0.14%)
At close: 4:00 PM EST
€28.70
<€0.01(0.14%)
Day’s Range― - ―
52-Week Range€4.10 - €47.66
Previous CloseN/A
Volume30.64K
Average Volume (3M)654.19K
Market Cap
€1.70B
Enterprise Value€1.60B
Total Cash (Recent Filing)€52.75M
Total Debt (Recent Filing)€95.32M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Sep 30, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding50,619,583
10 Day Avg. Volume711,483
30 Day Avg. Volume654,186
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-10.94
Price to Sales (P/S)31.19
P/FCF Ratio-27.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€55.00Price Target Upside91.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.2
Revenue Forecast (FY)€34.72M
Bulls Say, Bears Say
Bulls Say
NBTXR3 Nanoparticle Radiotherapy PlatformNBTXR3’s differentiated mechanism—engineered hafnium oxide nanoparticles that potentiate radiotherapy and stimulate immune responses—represents a platform technology. If clinical and regulatory milestones are achieved, this durable scientific moat can enable multiple indications and long-term commercial opportunities across solid tumors.
Strategic Collaboration With JanssenA global strategic partnership with a major pharma like Janssen provides non-dilutive funding, development and commercialization expertise, and milestone/royalty economics that materially de-risk late-stage development and expand commercialization reach, strengthening long-term execution capacity.
Broad Clinical Program Across Solid TumorsA multi-indication clinical program spreads development risk and creates multiple commercial pathways. Diversified indications increase the probability of at least one successful approval and allow for scalable adoption if the mechanism proves broadly effective, supporting durable revenue potential.
Bears Say
Consistent Operating Cash BurnPersistent negative operating and free cash flow signal reliance on external financing to fund R&D and operations. Over months, continued cash burn raises refinancing and dilution risk, constrains investment in pivotal trials and commercialization, and limits the company's ability to self-fund growth.
Negative Shareholders' Equity And Rising DebtA negative equity base combined with increased debt materially weakens financial flexibility. This capital-structure strain elevates refinancing risk, raises borrowing costs, and increases the likelihood of dilutive financings or restrictive covenants that can hamper long-term strategic options.
Highly Volatile, Inconsistent RevenueWide swings in reported revenue demonstrate limited repeatable commercial traction and make cash-flow forecasting unreliable. For a company dependent on milestone and partner payments, inconsistent top-line performance undermines predictability and complicates scaling to sustained, profitable operations.
NANO FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest stock price was €4.10 and its highest was €47.66 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €1.70B.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Sep 30, 2026 which is in 88 days.
How were Nanobiotix SA’s earnings last quarter?
Currently, no data Available
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA does not currently pay dividends.
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate is -0.25.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 50,619,583 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in FR:NANO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanobiotix SA
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
NANO Stock 12 Month Forecast
Average Price Target
€55.00
▲(91.64% Upside)
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―
Options Prices
Currently, No data available
---